Matriks Biotek SHIKARI® Q-ATI (Quantitative)
Enzyme immunoassay for the quantitative determination of specific antibodies to infliximab in human serum and plasma with confirmation.
Infliximab (Remicade) was associated to the development of anti-Infliximab antibodies, even some were reported to be neutralizing, in various percentages of patients during therapy with the drug Remicade®. This might lead to severe complications. The Matriks Biotek Shikari Q-ATI ELISA Kit can be efficiently used for monitoring anti-Infliximab antibodies.
|Required Volume (µl)||20|
|Total Time (min)||140|
|Detection Limit (ng/mL)||15|
|Spike Recovery (%)||Between 85-115|
|Shelf Life (year)||1|
For Research Use Only
Manufactured by Matriks Biotek Co.
Questions about this product? Ready to place an order? Email us at firstname.lastname@example.org or give us a call: (650) 486-1541